Institutional Ownership
Fibrobiologics Inc
CUSIP 31573L204COM NEWQ1 2026
13D / 13G Filings
0
Schedule 13D/13G on record
Beneficial Filers
0
Distinct reporting persons
Largest Stake
—
Max % of class reported
Institutional Holders
14
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
Schedule 13D (activist) & 13G (passive) 5%+ ownership filings
No 13D/13G filings on record yet
Schedule 13D/13G beneficial-ownership filings from 2020–present are ingested from SEC EDGAR. Coverage expands as the backfill and daily crawler run.
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fund Evaluation Group, LLC | 51.8K | $68.4K |
| 2 | Geode Capital Management, LLC | 29.6K | $39.1K |
| 3 | Blackrock, Inc. | 24.6K | $32.5K |
| 4 | Cascade Financial Partners, LLC | 16.4K | $21.7K |
| 5 | Renaissance Technologies LLC | 16.0K | $21.1K |
| 6 | Ubs Group AG | 5.7K | $7.6K |
| 7 | Tower Research Capital LLC (Trc) | 460 | $607 |
| 8 | Western Wealth Management, LLC | 200 | $264 |
| 9 | Islay Capital Management, LLC | 169 | $223 |
| 10 | Osaic Holdings, Inc. | 154 | $203 |